#United States #San Diego #Class Action #stock losses #Sarepta Therapeutics

Legal Opportunity for Sarepta Investors

Investors in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) who have suffered substantial losses from purchasing securities between June 22, 2023, and June 24, 2025, are now presented with a pivotal opportunity. The law firm Robbins Geller Rudman & Dowd LLP has announced that affected investors can apply to be appointed as lead plaintiff in a class action lawsuit against the company, named Dolgicer v. Sarepta Therapeutics, Inc. This legal action, filed under case number 25-cv-05317 in the Southern District of New York, alleges serious violations of the Securities Exchange Act of 1934.

Background on Sarepta Therapeutics

Sarepta Therapeutics is recognized as a commercial-stage biopharmaceutical firm focused on developing innovative therapies aimed at treating Duchenne muscular dystrophy (Duchenne). One of its notable products is ELEVIDYS, a gene therapy designed specifically for a select group of patients suffering from this condition.

Allegations Against Sarepta

According to the class action complaint, during the stipulated class period, management at Sarepta allegedly made multiple misleading statements about the safety and efficacy of ELEVIDYS. Specific concerns include the following:
1. Safety Risks: There were significant safety risks associated with ELEVIDYS that were not disclosed adequately.
2. Regulatory Compliance: The trial protocols in place failed to identify severe side effects, which led to life-threatening outcomes for patients.
3. Impact of Adverse Events: The severity of adverse events related to ELEVIDYS prompted Sarepta to pause patient recruitment and dosing in several studies, thereby attracting scrutiny from regulators.

Key Events Leading to the Lawsuit

The lawsuit outlines critical events that underscored the danger posed by ELEVIDYS, including:
1. March 18, 2025: A patient administered ELEVIDYS tragically succumbed to acute liver failure, a serious complication that had not been previously reported in relation to this therapy. Following this revelation, Sarepta's stock plummeted more than 27%.
2. April 4, 2025: Subsequent disclosures revealed that EU regulatory authorities had called for a review of the data monitoring committee due to the aforementioned death, resulting in additional stock value erosion of over 7%.
3. June 15, 2025: News of a second patient fatality from ELEVIDYS, related to acute liver failure, led to a suspension of shipments and paused clinical studies as investigations took place. This event resulted in a staggering 42% decrease in Sarepta's stock value.
4. June 24, 2025: The FDA issued a Safety Communication, reporting investigations into the risks associated with ELEVIDYS that could result in serious complications. This news triggered yet another drop in stock price by more than 8%.

The Role of Lead Plaintiff

Under the Private Securities Litigation Reform Act of 1995, any investor who acquired Sarepta securities during the defined class period is entitled to seek lead plaintiff status. The selected lead plaintiff will represent the interests of the entire class and has the privilege of choosing the law firm to oversee the lawsuit. It’s vital to note that an investor's recovery potential is not contingent on their role as lead plaintiff.

About Robbins Geller

Robbins Geller Rudman & Dowd LLP is recognized as one of the preeminent law firms in the realm of securities fraud and shareholder litigation. The firm prides itself on achievements such as being ranked #1 in the ISS Securities Class Action Services for recovering funds for investors on multiple occasions. In 2024 alone, they secured over $2.5 billion for clients in similar litigation, showcasing their commitment and capability in protecting investors’ rights.

If you experienced significant losses with Sarepta investments, you are encouraged to explore your eligibility to join this class action lawsuit. For more information on becoming a lead plaintiff, please visit Robbins Geller’s class action webpage or contact attorneys J.C. Sanchez or Jennifer N. Caringal directly at 800-449-4900 or via email at [email protected].